STERIS Reports 7.3% Revenue Growth in Fiscal Q1, Affirms Internal Controls
The infection prevention products giant posted stronger operating income and margins while maintaining effective disclosure controls, though free cash flow declined year-over-year.
Q1 Performance Shows Broad-Based Growth
STERIS plc, the $23 billion infection prevention products and services provider, reported revenue of $1,492.7 million for the three months ended June 30, 2026, representing a 7.3% increase from $1,391.1 million in the prior-year period (10-Q filing, 2026-08-07). The company attributed the growth to "higher volume in the Healthcare and Life Sciences segments, and pricing across all three segments."
Gross profit margin expanded to 45.8% from 45.1% year-over-year, driven by "favorable impacts from pricing, productivity and mix" that partially offset inflation pressures. Operating income rose to $285.8 million from $246.0 million in the first quarter of fiscal 2026, reflecting increased pricing, volume, and productivity gains, though these were "partially offset by inflation and additional spending on operational investments and staffing."
Cash Flow Declines Despite Earnings Growth
While operating performance strengthened, STERIS saw cash generation moderate in the quarter. Operating cash flow declined to $367.1 million from $420.0 million in the prior-year period, while free cash flow fell to $279.6 million from $326.5 million. The company attributed the decrease to "a significantly lower contribution from working capital partially offset by higher net income compared with fiscal 2026."
The company's debt-to-total capital ratio improved slightly to 20.9% at June 30, 2026, from 21.3% at March 31, 2026. STERIS declared and paid cash dividends totaling $0.63 per ordinary share during the quarter. According to MarginX data, the company has announced a $0.69 dividend payable September 4, 2026.
Tuck-In Acquisitions and Risk Management
STERIS completed three tuck-in acquisitions during the first quarter of fiscal 2027, "which continued to expand our product and service offerings in the Healthcare segment," with total consideration of approximately $17.3 million. Acquisition and integration expenses totaled $1.5 million for the quarter, compared to $0.5 million in the prior-year period.
The filing disclosed the company's hedging activities to manage market risks. At June 30, 2026, STERIS held foreign currency forward contracts to sell 48.0 million euros, 7.0 million Australian dollars, and 7.0 million New Zealand dollars, and to buy 175.0 million Mexican pesos. The company also held commodity swap contracts to buy 0.5 million pounds of nickel to hedge price changes affecting raw materials.
Notably, STERIS "did not elect hedge accounting for these forward currency contracts," which may result in volatility from timing mismatches between unrealized hedge gains or losses and recognition of underlying hedged earnings.
Controls Deemed Effective
Under the supervision of the company's Principal Executive Officer and Principal Financial Officer, STERIS evaluated its disclosure controls and procedures as of June 30, 2026. Management "concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were effective." The filing further noted that "there were no changes in our internal control over financial reporting" during the quarter that materially affected such controls.
MarginX data shows the company is expected to report Q2 fiscal 2027 results on November 4, 2026, with the next FOMC rate decision scheduled for September 16, 2026.
This article was generated by MarginX from the 10-Q filing on 2026-08-07. It is not investment advice.